The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| (gain) loss on disposal of fixed assets | - | 330 |
| Gain on change in derivative liability | - | 418,681 |
| Net loss | 17,200,488 | -11,790,697 |
| Depreciation and amortization | 248,253 | 504,629 |
| Amortization of operating lease right-of-use assets | 60,774 | 122,180 |
| Amortization of debt discount | 1,054,935 | - |
| Loss on disposal of fixed assets | -330 | - |
| Gain on change in fair value of warrant liability | - | -42,726 |
| Gain on change in derivative liability | 723,124 | - |
| Stock-based compensation | 609,167 | 1,263,419 |
| Loss (gain) on change in fair value of warrant liability | -14,884 | - |
| Prepaid expenses | -14,398 | 135,808 |
| Accounts receivable | 119,488 | 79,023 |
| Management and directors' fees payable | - | 24,306 |
| Other current assets | 20,269 | 101 |
| Deferred revenue, current and non-current | -405,072 | -107,559 |
| Accounts payable and accrued liabilities | 993,076 | -188,884 |
| Management and directors' fees payable | 85,736 | - |
| Amortization of debt discount | - | 325,305 |
| Operating leases liabilities | -61,243 | -122,189 |
| Net cash used in operating activities | -3,630,760 | -10,560,707 |
| Purchases of property and equipment | 0 | 78,591 |
| Purchase of license | 0 | 0 |
| Net cash used in investing activities | 0 | -78,591 |
| Net proceeds from issuances of common stock | 2,007,419 | 2,447,214 |
| Tax withholdings paid related to stock-based compensation | 80,381 | 79,468 |
| Proceeds from grants repayable | 32,426 | - |
| Proceeds from long-term debt | 0 | 1,570,176 |
| Net proceeds from issuance of convertible note and warrants | -28,597 | 5,802,799 |
| Payments on long-term debt | 285,350 | 411,824 |
| Payments on grants repayable | 32,426 | -32,426 |
| Payments on finance lease liabilities | 13,142 | 24,219 |
| Net cash provided by financing activities | 1,599,949 | 9,337,104 |
| Effect of foreign exchange on cash | -25,778 | 293,761 |
| Net change in cash and cash equivalents | -2,056,589 | -1,008,433 |
| Cash and cash equivalents at beginning of period | 3,264,429 | - |
| Cash and cash equivalents at end of period | 199,407 | - |
VOLITIONRX LTD (VNRX)
VOLITIONRX LTD (VNRX)